Lexette (halobetasol propionate foam) / Mayne Pharma - LARVOL DELTA

"$MYPHY FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis https://t.co/EU9vY4g7iS" (@stock_titan)

FDA event • Dermatology • Immunology • Psoriasis

[VIRTUAL] Mayne Pharma_Evaluaiton of Adrenal Suppression Potential of Halobetasol Foam in Adolescent Patients with Plaque Psoriasis_Hebert et al. 2020 (SDDS 2021) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis (clinicaltrials.gov) - P4; N=30; Not yet recruiting; Sponsor: Skin Sciences, PLLC

Clinical • New P4 trial • Dermatology • Immunology • Psoriasis

Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis (clinicaltrials.gov) - P4; N=23; Completed; Sponsor: Mayne Pharma International Pty Ltd; Recruiting ➔ Completed; Trial primary completion date: Sep 2019 ➔ Dec 2019

Clinical • Trial completion • Trial primary completion date

Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis (clinicaltrials.gov) - P4; N=25; Recruiting; Sponsor: Mayne Pharma International Pty Ltd

Clinical • New P4 trial

FDA approves trade name Lexette (halobetasol propionate) foam, 0.05% (PRNewswire) - "Mayne Pharma Group Limited...is pleased to announce that the US Food and Drug Administration (FDA) has approved the trade name LEXETTE™ for the approved drug halobetasol propionate foam, 0.05%."

sNDA

Mayne Pharma launches Lexette (halobetasol propionate) foam 0.05% in the United States (PRNewswire) - "Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of LEXETTE™ (halobetasol propionate) Foam 0.05% in the United States."

Launch US